Form D · Biotechnology
BioPlx, Inc.
Boulder, CO · CIK 0001681636
Offering snapshot reported Feb 25, 2020 · SEC filing
- Reported sold
- $1.08M Offering amount: $4M
- Investors reported
- 2 Form D · investor count
- Minimum accepted
- $100K Reported outside-investor minimum
- First sale
- Feb 18, 2020 As reported in this filing
What changed?
Latest filing versus its linked predecessor, where available.
No comparable changes in the displayed metrics.
Filing history
Scroll to see all columns →
| Filed | Filing type | Reported sold | Change vs linked filing | Investors | Source |
|---|---|---|---|---|---|
| Feb 25, 2020 | Initial | $1,075,889 | No comparison | 2 | SEC filing |
| Aug 19, 2019 | Amendment | $1,641,415 | $10,000vs Jun 25, 2019 | 12 | SEC filing |
| Jun 25, 2019 | Initial | $1,631,415 | No comparison | 11 | SEC filing |
Offering details
- Securities
- Equity
- Exemptions
- 06b
- Duration over one year
- No
- Business combination
- No
- Sales commissions
- $0
- Finders' fees
- $0
- Form D file number
- 021-361253
Source: Form D, filed Feb 25, 2020. Minimum accepted may differ from a standard advertised minimum.
Fund connections
No confirmed ADV fund connection is available for this issuer.
People & organizations
Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.
| Name | Reported role |
|---|---|
| Norman Stuart Harris | Director |
| Ravi Starzl | Director, Executive |
| Timothy Starzl | Director, Executive |
| Bimla Starzl | Director, Executive |
Issuer details
Industry: Biotechnology (See others in industry)
Address:
1800 30 Th Street #213
Boulder, CO, 80301
Boulder, CO, 80301